Trials / Completed
CompletedNCT03871595
A Study in Healthy Men to Test Whether Food Affects the Amount of BI 894416 in the Blood
Relative Bioavailability of BI 894416 as Tablet Formulation Following a High-fat, High-calorie Breakfast Compared to Administration in the Fasting State in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Investigate the relative bioavailability of BI 894416 as tablet formulation following a high-fat, high calorie breakfast (Test, T) compared with administration in the fasting state (Reference, R)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 894416 | 3 tablets with 10 milligram (mg) of BI 894416 (total: 30 mg) were administered as one single oral dose with 240 milliliter (mL) of water. |
Timeline
- Start date
- 2019-03-20
- Primary completion
- 2019-04-24
- Completion
- 2019-04-24
- First posted
- 2019-03-12
- Last updated
- 2023-08-14
- Results posted
- 2023-08-14
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03871595. Inclusion in this directory is not an endorsement.